# Judge Denies SAM’s Temporary Restraining Order; CBD Pilot Program Launches > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cbd-pilot-programs-launch-judge-denies-sam-order/ > **Published:** 2026-04-01T16:06:19-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:32:41-04:00 > **Clinical Summary:** CBD pilot programs launch following a judge's denial of SAM's temporary restraining order, enabling controlled clinical research and regulatory oversight. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic Cbd[Clinical Research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/)Regulatory PolicyEvidence-Based MedicineLegal Framework Why This Matters CBD pilot programs represent controlled opportunities to generate real-world safety and efficacy data under regulatory oversight. These programs can inform evidence-based prescribing guidelines and help establish standardized dosing protocols that are currently lacking in clinical practice. Clinical Summary A judge has denied Smart Approaches to Marijuana’s (SAM) request for a temporary restraining order that would have halted a CBD pilot program. The program can now proceed as planned, allowing for controlled study of [CBD products](https://cedclinic.com/fda-warning-on-cbd-products/) under regulatory framework. This represents a legal victory for research-oriented approaches to [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/), particularly for CBD which has established safety profiles but limited standardized clinical protocols. The pilot program structure typically involves tracked products, defined patient populations, and systematic data collection. Dr. Caplan’s Take “I see pilot programs as essential infrastructure for evidence generation – they bridge the gap between limited FDA-approved options and the wild west of unregulated products. When courts protect these research pathways, patients ultimately benefit from better data.” Clinical Perspective 🧠 Clinicians should monitor outcomes from these pilot programs as they often provide the most rigorous real-world evidence available for CBD dosing and safety profiles. Patients participating in pilot programs typically receive higher quality products with better testing and tracking than retail alternatives. This legal precedent may encourage similar research-focused programs in other jurisdictions. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Judge%20Denies%20SAM%27s%20Temporary%20Restraining%20Order%3B%20CBD%20Pilot%20Program%20Launches%20%40drcaplan&url=https%3A//www.cannabisbusinesstimes.com/business-issues-benchmarks/cbd-industry/news/15821141/judge-denies-sams-temporary-restraining-order-cbd-pilot-program-launches)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.cannabisbusinesstimes.com/business-issues-benchmarks/cbd-industry/news/15821141/judge-denies-sams-temporary-restraining-order-cbd-pilot-program-launches)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Judge%20Denies%20SAM%27s%20Temporary%20Restraining%20Order%3B%20CBD%20Pilot%20Program%20Launches%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.cannabisbusinesstimes.com/business-issues-benchmarks/cbd-industry/news/15821141/judge-denies-sams-temporary-restraining-order-cbd-pilot-program-launches)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.cannabisbusinesstimes.com/business-issues-benchmarks/cbd-industry/news/15821141/judge-denies-sams-temporary-restraining-order-cbd-pilot-program-launches](https://www.cannabisbusinesstimes.com/business-issues-benchmarks/cbd-industry/news/15821141/judge-denies-sams-temporary-restraining-order-cbd-pilot-program-launches) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating of this cannabis news?](#What_is_the_clinical_relevance_rating_of_this_cannabis_news) - [What type of cannabis research does this relate to?](#What_type_of_cannabis_research_does_this_relate_to) - [Why is this classified as “Notable Clinical Interest”?](#Why_is_this_classified_as_8220Notable_Clinical_Interest8221) - [What areas of medicine does this CBD research cover?](#What_areas_of_medicine_does_this_CBD_research_cover) - [How should healthcare professionals use this information?](#How_should_healthcare_professionals_use_this_information) - [Related](#Related) ## FAQ #### What is the clinical relevance rating of this cannabis news? This article has been assigned CED Clinical Relevance #70, which indicates “Notable Clinical Interest.” This rating signifies emerging findings or policy developments that are worth monitoring closely by healthcare professionals. #### What type of cannabis research does this relate to? This news pertains to CBD [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) and regulatory policy developments. The focus appears to be on evidence-based medicine applications of cannabidiol in clinical settings. #### Why is this classified as “Notable Clinical Interest”? The Notable Clinical Interest classification suggests this involves emerging research findings or policy changes that could impact clinical practice. Healthcare providers should monitor these developments as they may influence future treatment protocols or regulatory guidelines. #### What areas of medicine does this CBD research cover? Based on the tags, this research encompasses clinical applications of CBD within evidence-based medicine frameworks. The regulatory policy component suggests potential changes in how CBD treatments may be prescribed or administered clinically. #### How should healthcare professionals use this information? Healthcare professionals should monitor these developments closely as indicated by the clinical relevance rating. The emerging nature of these findings suggests they may inform future clinical guidelines or influence current evidence-based treatment approaches involving CBD. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Judge Denies SAM’s Temporary Restraining Order; CBD Pilot Program Launches”, “url”: “https://www.cannabisbusinesstimes.com/business-issues-benchmarks/cbd-industry/news/15821141/judge-denies-sams-temporary-restraining-order-cbd-pilot-program-launches”, “datePublished”: “2026-04-01T17:08:15Z”, “about”: “judge denies sam s temporary restraining”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Health expert to lead medical cannabis review | Irish Legal News](https://cedclinic.com/medical-cannabis-policy-review-ireland/) An expert leads a comprehensive review of medical cannabis programs, highlighting regulatory and clinical research advancements. [Read More](https://cedclinic.com/medical-cannabis-policy-review-ireland/) [Missouri sets sights on establishing licensed cannabis research • Missouri Independent](https://cedclinic.com/state-licensed-cannabis-research-programs-missouri/) Missouri aims to establish licensed [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) programs to enhance clinical evidence and regulatory frameworks. [Explore Details](https://cedclinic.com/state-licensed-cannabis-research-programs-missouri/) [Does Cannabis Legalization Spur More Innovation Than Medical Research?](https://cedclinic.com/cannabis-innovation-and-medical-research-balance/) An analysis of how [cannabis legalization](https://cedclinic.com/the-forgotten-history-of-hemp-in-america/) impacts innovation and medical research in the cannabis industry. [Learn More](https://cedclinic.com/cannabis-innovation-and-medical-research-balance/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).